Last reviewed · How we verify

NCT03167918

Lung Function in Patients With Early Type 2 Diabetes Mellitus

Completed Phase 2, PHASE3 Last updated 30 May 2017
What this trial tests

Phase 2, PHASE3 trial testing Calcium Dobesilate in Type 2 Diabetes Mellitus in 200 participants. Completed in 1 May 2017.

Timeline
21 July 2014
Primary endpoint
1 April 2017
1 May 2017

Quick facts

Lead sponsorLiaoning University of Traditional Chinese Medicine
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment200
Start date21 July 2014
Primary completion1 April 2017
Estimated completion1 May 2017

Drugs / interventions tested

Conditions studied

Sponsor

Liaoning University of Traditional Chinese Medicine

Who can join

Eligibility, any sex, with Type 2 Diabetes Mellitus or Pulmonary Function. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the protective effect of calcium dobesilate, Xuefuzhuyu Decoction, calcium dobesilate combined with Xuefuzhuyu Decoction on the early lung function of type 2 diabetes mellitus

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Calcium Dobesilate

Trials testing the same drug.

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03167918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing